About Accretion Pharmaceuticals Limited
Data last updated:
Accretion Pharmaceuticals Limited is a public limited company based in Sanand, Gujarat, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 29 November 2023.
The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L21004GJ2023PLC146545. Its GSTIN is 24AAZCA7550K1Z1 (Gujarat). It is a listed company as per MCA records. Its shares are listed on NSE: ACCPL.
The company has an authorised share capital of ₹13 Cr and a paid-up capital of ₹11.12 Cr. It is led by directors including Vivek Ashok Kumar Patel (Managing Director) and Chand Rameshbhai Kanabar.
Its last annual general meeting (AGM) was held on 27 August 2026, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 29 Xcelon Ind Park, Sanand, Gujarat.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹89.63 Cr, a growth of 56.2% compared to the previous year. For the same year it recorded a net profit of ₹9.66 Cr (net margin 10.8%) and EBITDA of ₹14.95 Cr (EBITDA margin 16.7%). The net worth stands at ₹54.71 Cr (up 257.8% YoY). Total assets are valued at ₹67.03 Cr (up 128.1% YoY).
As per MCA filings, the company has open charges of ₹15.1 Cr on record. Court records list 1 case involving the company, including 1 filed by the company; 1 case is pending. The company has 2 deals on record (1 rights issue, 1 ipo); the latest was in May 2025. Its 7 peer companies in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 3 smaller; the largest is Solistaa Pharmaceuticals Private Limited with revenue of ₹57.79 Cr.
For more details, the company can be reached via its website accretion.co.in.
Company details
CIN history
Accretion Pharmaceuticals has one previous CIN (Corporate Identification Number): U21004GJ2023PLC146545. The current CIN is L21004GJ2023PLC146545, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L21004GJ2023PLC146545 | Current |
| U21004GJ2023PLC146545 | Previous |
Contact details
Accretion Pharmaceuticals Limited's registered office is in Sanand, Gujarat.
- Registered Address29 Xcelon Ind Park 1 B/H, Intas Pharmaceuticals, Sanand, Gujarat, India – 382213
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Accretion Pharmaceuticals is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Accretion Pharmaceuticals Limited, buy the company report.
Financials of Accretion Pharmaceuticals Limited
FY 2025-26 filings availableAccretion Pharmaceuticals Limited reported revenue of ₹89.63 Cr (up 56.2% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Income statement | |||
| Revenue | 89.63 | 57.38 | 13.35 |
| Revenue growth | +56.2% | +329.8% | - |
| EBITDA | 14.95 | 11.88 | 2.56 |
| EBITDA margin | +16.7% | +20.7% | +19.2% |
| Profit before tax | 13.08 | 9.76 | 1.99 |
| Net profit | 9.66 | 6.79 | 1.49 |
| Net profit margin | +10.8% | +11.8% | +11.2% |
| EPS (₹) | 9.03 | 8.32 | 3.73 |
| Balance sheet | |||
| Total assets | 67.03 | 29.39 | 18.97 |
| Net worth | 54.71 | 15.29 | 5.49 |
| Total debt | 12.32 | 14.10 | 13.48 |
| Cash & bank | 4.02 | 0.05 | 0.09 |
| Net working capital | 51.01 | 23.14 | 13.58 |
| Cash flow | |||
| Cash from operations | (14.53) | (0.62) | (11.51) |
| Cash from investing | (8.53) | (1.61) | (5.48) |
| Cash from financing | 27.04 | 2.19 | 17.08 |
Financial Statements
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Revenue | 89.63 | 57.38 | 13.35 |
| Revenue growth | +56.2% | +329.8% | - |
| Other income | 0.19 | 0.09 | 0.05 |
| Total expenses | 74.68 | 45.50 | 10.79 |
| Employee cost | 0.00 | 3.04 | 0.79 |
| EBITDA | 14.95 | 11.88 | 2.56 |
| EBITDA margin | +16.7% | +20.7% | +19.2% |
| Depreciation | 1.21 | 0.77 | 0.22 |
| Interest | 0.85 | 1.44 | 0.40 |
| Profit before tax | 13.08 | 9.76 | 1.99 |
| Tax | 3.42 | 2.97 | 0.50 |
| Net profit | 9.66 | 6.79 | 1.49 |
| Net profit margin | +10.8% | +11.8% | +11.2% |
| EPS (₹) | 9.03 | 8.32 | 3.73 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Equity & liabilities | |||
| Share capital | 11.12 | 8.17 | 4.00 |
| Reserves & surplus | 43.59 | 7.12 | 1.49 |
| Shareholders' funds (net worth) | 54.71 | 15.29 | 5.49 |
| Secured loans | 8.98 | 9.62 | 5.24 |
| Unsecured loans | 3.34 | 4.48 | 8.24 |
| Total debt | 12.32 | 14.10 | 13.48 |
| Total liabilities | 67.03 | 29.39 | 18.97 |
| Assets | |||
| Gross block | 15.42 | 7.09 | 5.48 |
| Net block | 13.21 | 6.09 | 5.26 |
| Capital work in progress | 0.20 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 |
| Inventories | 28.37 | 20.61 | 14.48 |
| Sundry debtors | 22.40 | 11.66 | 5.80 |
| Cash & bank balances | 4.02 | 0.05 | 0.09 |
| Loans & advances | 5.60 | 1.12 | 1.68 |
| Total current assets | 60.39 | 33.44 | 22.05 |
| Total current liabilities | 9.38 | 10.30 | 8.47 |
| Net working capital | 51.01 | 23.14 | 13.58 |
| Total assets | 67.03 | 29.39 | 18.97 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Opening cash | 0.05 | 0.09 | 0.00 |
| Net cash from operating activities | (14.53) | (0.62) | (11.51) |
| Net cash from investing activities | (8.53) | (1.61) | (5.48) |
| Net cash from financing activities | 27.04 | 2.19 | 17.08 |
| Net change in cash | 3.97 | (0.04) | 0.09 |
| Closing cash | 4.02 | 0.05 | 0.09 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Growth | |||
| Sales growth | +56.2% | +329.8% | - |
| EBITDA growth | +25.8% | +364.1% | - |
| PBT growth | +34.0% | +390.5% | +9997.0% |
| Net income growth | +42.3% | +355.7% | - |
| Profitability & leverage | |||
| Net income margin | +10.8% | +11.8% | +11.2% |
| Return on capital employed | - | +46.3% | +12.6% |
| Return on net worth | - | +65.4% | +27.1% |
| Debt / equity | - | 1.33 | 2.46 |
| Long-term debt / equity | - | 0.39 | 1.26 |
| Interest cover | 6.19 | 12.96 | 17.09 |
| Efficiency & per share | |||
| Fixed asset turnover | - | 9.13 | 2.44 |
| Inventory turnover | - | 3.27 | 0.92 |
| Debtors turnover | - | 6.57 | 2.30 |
| EPS (₹) | 9.03 | 8.32 | 3.73 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 18.71 | 13.73 |
To see the full year-wise statements and ratios of Accretion Pharmaceuticals Limited, buy the company report.
Board of directors of Accretion Pharmaceuticals Limited
Accretion Pharmaceuticals has 7 current directors and 7 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Chand Rameshbhai Kanabar Also directs: Golden Sparrow Consultancy Private Limited | Director | 19 Apr 2025 | 1 Years 6 Months | Current |
| Nishtha Harivanshi Pamnani Also directs: Prashant India Limited, Kore Digital Limited | Director | 10 Jun 2025 | 1 Years 4 Months | Current |
| Grishma A Shewale Also directs: Curis Lifesciences Limited, Bipin Offset Limited | Director | 09 Jul 2024 | 2 Years 3 Months | Current |
| Mayur Popatlal Sojitra Also directs: Accretion Nutraveda Limited, Accresha Lifecare Private Limited | Director | 29 Nov 2023 | 2 Years 10 Months | Current |
| Harshad Nanubhai Rathod Also directs: Accretion Nutraveda Limited | Director | 29 Nov 2023 | 2 Years 10 Months | Current |
| Vivek Ashok Kumar Patel Also directs: Accretion Nutraveda Limited | Managing Director | 29 Nov 2023 | 2 Years 10 Months | Current |
Peer comparison
Accretion Pharmaceuticals Limited is compared with the 7 companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Accretion Pharmaceuticals Limitedthis company | ₹89.63 Cr (FY 2026) | ₹9.66 Cr | 10.8% | 56.2% | Sanand, Gujarat, India | |
| Solistaa Pharmaceuticals Private Limited | ₹57.79 Cr (FY 2025) | 8.0% | Puducherry, India | |||
| Stedman Pharmaceuticals Private Limited | ₹57.77 Cr (FY 2024) | 9.0% | Chennai, Tamil Nadu, India | |||
| And Healthcare Limited | ₹57.48 Cr (FY 2024) | 24.0% | Mohali, Punjab, India | |||
| Alna Biotech Private Limited | ₹57.47 Cr (FY 2024) | 3.0% | Chandigarh, India | |||
| VPL Chemicals Private Limited | ₹57.32 Cr (FY 2025) | 23.0% | Bangalore, Karnataka, India | |||
| Alidac Pharmaceuticals Limited | ₹57.16 Cr (FY 2019) | -60.0% | Matoda, Gujarat, India | |||
| Samrat Remedies India Private Limited | ₹57.12 Cr (FY 2024) | 29.0% | Mumbai, Maharashtra, India |
To see the full peer comparison of Accretion Pharmaceuticals Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 05 Jan 2024 | 100844260 | Indian Bank | ₹15.1 Cr | Open |
To see the full charge records of Accretion Pharmaceuticals Limited, buy the company report.
Total charge records: 1 View all charges
Deals & funding
Accretion Pharmaceuticals Limited has 2 deals on record (1 rights issue, 1 ipo); the latest was in May 2025.
Deals on record (2 of 2)
| When | Deal | Amount | Parties |
|---|---|---|---|
| May 2025 | IPO | ₹29.76 Cr | Investors: Ipo Shareholders - Accretion Pharmaceuticals Limited, Pink Oak Global Fund, Vikasa India Eif I Fund - Incube Global Opportunities |
| Jul 2024 | Rights issue | ₹3 Cr | Investors: 4 individuals |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Accretion Pharmaceuticals Limited has 1 court case on record: 1 filed by Accretion Pharmaceuticals. All case is pending.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 1 | 0 | 1 |
Cases on record (1 of 1)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court of Karnataka | Writ petition | Filed by the company against The State of Karnataka | Pending |
To see the full case history of Accretion Pharmaceuticals Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Accretion Pharmaceuticals Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Accretion Pharmaceuticals has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 24AAZCA7550K1Z1 | Gujarat | Active | 29 Nov 2023 |
To see the full GST registrations and return filing status of Accretion Pharmaceuticals Limited, buy the company report.
Recent activity
Accretion Pharmaceuticals Limited has 14 board changes on record since 2023: 7 appointments and 7 cessations. The latest: Chand Rameshbhai Kanabar ceased to be Additional Director on 24 Sep 2025.
7 earlier events are in the company report.
News
Frequently asked questions
Accretion Pharmaceuticals is an active public limited company based in Sanand, Gujarat, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 29 November 2023 (3+ years old) and is registered under CIN L21004GJ2023PLC146545. Listed on NSE: ACCPL.
Accretion Pharmaceuticals reported revenue of ₹89.63 Cr for FY 2025-26 (up 56.2% YoY) based on standalone financials.
Accretion Pharmaceuticals has 7 current directors:
- Vivek Ashok Kumar Patel - Managing Director
- Chand Rameshbhai Kanabar - Director
- Nishtha Harivanshi Pamnani - Director
- Grishma A Shewale - Director
- Mayur Popatlal Sojitra - Director
- Harshad Nanubhai Rathod - Director
- Hardik Mukundbhai Prajapati - Director
The latest financial statements of Accretion Pharmaceuticals on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 27 August 2026. Year-wise statements from FY 2024 are in the company report.
The GSTIN of Accretion Pharmaceuticals is 24AAZCA7550K1Z1, registered in Gujarat.
The CIN (Corporate Identification Number) of Accretion Pharmaceuticals is L21004GJ2023PLC146545. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Accretion Pharmaceuticals is a listed company as per MCA records. Its shares are listed on NSE (symbol: ACCPL).
Accretion Pharmaceuticals has 1 court case on record: 1 filed by the company. 1 is pending.
Accretion Pharmaceuticals was incorporated on 29 November 2023, making it 3+ years old. It is registered with the Registrar of Companies, Ahmedabad.
Accretion Pharmaceuticals has 2 deals on record (1 rights issue, 1 ipo); the latest was in May 2025.
The peers of Accretion Pharmaceuticals by revenue are Solistaa Pharmaceuticals Private Limited, Stedman Pharmaceuticals Private Limited, And Healthcare Limited, Alna Biotech Private Limited, VPL Chemicals Private Limited and 2 more, all in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).